UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000008821 |
|---|---|
| Receipt number | R000010279 |
| Scientific Title | Study of the efficacy and safety of maintenance Irinotecan in patients with extended small cell lung cancer after 4 courses of Cisplatin plus Irinotecan chemotherapy. |
| Date of disclosure of the study information | 2012/08/31 |
| Last modified on | 2015/05/15 08:59:26 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Study of the efficacy and safety of maintenance Irinotecan in patients with extended small cell lung cancer after 4 courses of Cisplatin plus Irinotecan chemotherapy.
Acronym
Maintenance Irinotecan
Scientific Title
Study of the efficacy and safety of maintenance Irinotecan in patients with extended small cell lung cancer after 4 courses of Cisplatin plus Irinotecan chemotherapy.
Scientific Title:Acronym
Maintenance Irinotecan
Region
| Japan |
Condition
Condition
extended small cell lung cancer
Classification by specialty
| Pneumology | Hematology and clinical oncology |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
To evaluate the efficacy and safety of maintenance Irinotecan in patients with extended small cell lung cancer and achieved PR or CR response after 4 courses of Cisplatin plus Irinotecan chemotherapy.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
feasibility at 6 months
Key secondary outcomes
overall survival
progression-free survival
response rate
rate of adverse events
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
Four cycles of Cicplatin(60mg/m2 day1)and Irinotecan(60mg/m2 day1, 8,15) followed by maintenance Irinotecan(CPT-11)(60mg/m2 day1, 8,15) until disease progression.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 70 | years-old | >= |
Gender
Male and Female
Key inclusion criteria
1)Pathologically diagnosed as small cell lung cancer
2)Diagnosed as extended small cell lung cancer based on chest CT, abdominal CT, bone scintigraphy or brain MRI at the onset of disease.
3)Age 20=<,70=>
4)ECOG PS0or1
5)Measurable or nonmeasrurable lesions
6)CR or PR is achieved after the prior chemotherapy of Cisplatin (60mg/m2) and Irinotecan(60mg/m2 day1,8,15) .
7)Administered at least 9 times Irinotecan in prior IP chemotherapy
8)Registered after irradiated PCI, in the case of brain metastasis was not found before the prior chemotherapy. PCI is not always required.
9)Registered after irradiated WBRT(3Gy/Fr total 30Gy) after the prior IP chemotherapy , in the case of brain metastasis was found before the prior chemotherapy. WBRT is required.
10)No history of chemotherapy for other than lung cancer, and radiotherapy or surgery for primary lung cancer.
11)Adequate organ function, evaluated within 14 days before enrollment as;
1.WBC >=3,000/mm3 and Neutrophil >=1,500/mm3
1.Hemoglobin >=9.0 g/dL
3.Platelets >=100,000/mm3
4.Total bilirubin <=2.0mg/mL
5.GOT(AST)<=100 IU/L
6.GPT(ALT)<=100 IU/L
7.Serum creatinine <=1.5 mg/dL
8.PaO2>=70mmHg or SpO2>=95%
9.Normal electrocardiogram
12)Passed 4 weeks and over, under 8 weeks, from the last day of the administration of the IP chemotherapy.
13)Expected to live over 3 months from the first day of the chemotherapy.
14)Written informed consent from the patients.
Key exclusion criteria
1)Active multiple malignacy
2)Grave complications
3)Bacterial infectious or fungus infection
4)Diarrhea
5)Paresis of intestine or ileus
6)Interstitial pneumonia or pulmonary fibrosis on chest CT
7)Dose of Irinotecan in prior chemotherapy is >60 mg/m2 at fourth course
8)Uncontrolled diabetes
9)Grave heart disease
10)Psychological disease decided not to be registered to this study
11)Pregnant or lactating women
12)Gastroduodenal ulcer
13)Grave complications
14)Doctor's decision not to be registered to this study
Target sample size
28
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Yuichiro Ohe |
Organization
National Cancer Center Hospital East
Division name
Division of Thoracic Oncology
Zip code
Address
6-5-1, Kashiwanoha, Kashiwa, Chiba, Japan
TEL
04-7133-1111
yohe@east.ncc.go.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Shigeki Umemura |
Organization
National Cancer Center Hospital East
Division name
Division of Thoracic Oncology
Zip code
Address
6-5-1, Kashiwanoha, Kashiwa, Chiba, Japan
TEL
04-7133-1111
Homepage URL
sumemura@east.ncc.go.jp
Sponsor or person
Institute
Division of Thoracic Oncology, National Cancer Center Hospital East
Institute
Department
Personal name
Funding Source
Organization
National Cancer Center Research and developing found
Organization
Division
Category of Funding Organization
Other
Nationality of Funding Organization
Japan
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
国立がん研究センター東病院（千葉県）
国立がん研究センター中央病院（東京都）
がん感染症センター都立駒込病院
癌研究会有明病院
横浜市立市民病院
新潟県立がんセンター新潟病院
兵庫県立がんセンター
近畿大学医学部
岡山大学医学部・歯学部付属病院
国立病院機構山口宇部医療センター
国立病院機構四国がんセンター
国立病院機構九州がんセンター
Other administrative information
Date of disclosure of the study information
| 2012 | Year | 08 | Month | 31 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2012 | Year | 07 | Month | 19 | Day |
Date of IRB
Anticipated trial start date
| 2012 | Year | 08 | Month | 07 | Day |
Last follow-up date
| 2015 | Year | 02 | Month | 16 | Day |
Date of closure to data entry
| 2015 | Year | 02 | Month | 16 | Day |
Date trial data considered complete
| 2015 | Year | 02 | Month | 16 | Day |
Date analysis concluded
| 2015 | Year | 02 | Month | 16 | Day |
Other
Other related information
Management information
Registered date
| 2012 | Year | 08 | Month | 31 | Day |
Last modified on
| 2015 | Year | 05 | Month | 15 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000010279
